Relaxin reduces xenograft tumour growth of human MDA-MB-231 breast cancer cells
2008

Relaxin Reduces Tumor Growth in Breast Cancer Cells

Sample size: 10 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yvonne Radestock, Hoang-Vu Cuong, Hombach-Klonisch Sabine

Primary Institution: Martin-Luther-University Halle Wittenberg

Hypothesis

The study investigates the effects of relaxin on cancer cell motility and tumor growth in oestrogen-independent breast cancer cells.

Conclusion

Long-term exposure to relaxin inhibits tumor growth and reduces cell motility in oestrogen-independent breast cancer cells.

Supporting Evidence

  • Relaxin increased cell motility in the short term but reduced it in the long term.
  • Stable MDA/RLN2 transfectants produced smaller tumors with lower S100A4 levels.
  • Relaxin's effects were mediated through the down-regulation of the protein S100A4.

Takeaway

Relaxin can help slow down the growth of certain breast cancer tumors and make the cancer cells less active.

Methodology

The study used stable transfectants of MDA-MB-231 cells to assess the effects of relaxin on cell motility and tumor growth in vivo.

Limitations

The study did not observe metastasis due to the short duration of the experiment.

Statistical Information

P-Value

p<0.005

Statistical Significance

p<0.005

Digital Object Identifier (DOI)

10.1186/bcr2136

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication